Compare ASTRAZENECA PHARMA with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ABBOTT INDIA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ABBOTT INDIA ASTRAZENECA PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 88.0 47.6 185.2% View Chart
P/BV x 24.8 13.6 182.1% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ASTRAZENECA PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ABBOTT INDIA
Mar-18
ASTRAZENECA PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,2786,110 20.9%   
Low Rs8833,996 22.1%   
Sales per share (Unadj.) Rs228.41,552.2 14.7%  
Earnings per share (Unadj.) Rs10.4188.8 5.5%  
Cash flow per share (Unadj.) Rs16.3196.4 8.3%  
Dividends per share (Unadj.) Rs055.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs98.8796.6 12.4%  
Shares outstanding (eoy) m25.0021.25 117.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.3 145.3%   
Avg P/E ratio x104.226.8 389.5%  
P/CF ratio (eoy) x66.425.7 258.3%  
Price / Book Value ratio x10.96.3 172.4%  
Dividend payout %029.1 0.0%   
Avg Mkt Cap Rs m27,008107,376 25.2%   
No. of employees `0001.43.3 40.8%   
Total wages/salary Rs m1,5353,937 39.0%   
Avg. sales/employee Rs Th4,210.99,929.3 42.4%   
Avg. wages/employee Rs Th1,132.21,185.1 95.5%   
Avg. net profit/employee Rs Th191.11,207.7 15.8%   
INCOME DATA
Net Sales Rs m5,71032,985 17.3%  
Other income Rs m1231,170 10.5%   
Total revenues Rs m5,83334,155 17.1%   
Gross profit Rs m4635,245 8.8%  
Depreciation Rs m147162 91.0%   
Interest Rs m038 0.0%   
Profit before tax Rs m4386,215 7.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1792,203 8.1%   
Profit after tax Rs m2594,012 6.5%  
Gross profit margin %8.115.9 51.0%  
Effective tax rate %40.835.4 115.2%   
Net profit margin %4.512.2 37.3%  
BALANCE SHEET DATA
Current assets Rs m3,20922,655 14.2%   
Current liabilities Rs m2,0706,681 31.0%   
Net working cap to sales %20.048.4 41.2%  
Current ratio x1.63.4 45.7%  
Inventory Days Days7265 111.7%  
Debtors Days Days3529 119.8%  
Net fixed assets Rs m790835 94.6%   
Share capital Rs m50213 23.5%   
"Free" reserves Rs m2,41916,715 14.5%   
Net worth Rs m2,46916,928 14.6%   
Long term debt Rs m00-   
Total assets Rs m4,60524,162 19.1%  
Interest coverage xNM163.7-  
Debt to equity ratio x00-  
Sales to assets ratio x1.21.4 90.8%   
Return on assets %5.616.8 33.6%  
Return on equity %10.523.7 44.3%  
Return on capital %17.736.9 48.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m300369 81.3%   
Fx outflow Rs m2,0153,807 52.9%   
Net fx Rs m-1,715-3,438 49.9%   
CASH FLOW
From Operations Rs m881,527 5.8%  
From Investments Rs m-94-2,148 4.4%  
From Financial Activity Rs mNA-1,024 0.0%  
Net Cashflow Rs m-6-1,646 0.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 0.3 7.9 3.8%  
FIIs % 15.7 0.1 15,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.1 53.2%  
Shareholders   12,856 18,270 70.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALEMBIC LTD  AUROBINDO PHARMA  IPCA LABS  FDC LTD.  SUN PHARMA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Realty and Telecom Stocks Drag(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is flat while the Hang Seng is down 0.9%.

Related Views on News

ASTRAZENECA PHARMA at 52 Week High; BSE 500 Index Down 0.1 % (Market Updates)

Oct 23, 2019 | Updated on Oct 23, 2019

ASTRAZENECA PHARMA share price has hit a 52-week high. It is presently trading at Rs 2,470. BSE 500 Index is down by 0.1% at 15,036. Within the BSE 500, ASTRAZENECA PHARMA (up 2.4%) and ASTER DM HEALTHCARE LTD (up 5.8%) are among the top gainers, while top losers are RBL BANK LTD and DISH TV.

LAURUS LABS LTD Surges by 9%; BSE HEALTHCARE Index Up 0.2% (Market Updates)

Oct 23, 2019 | Updated on Oct 23, 2019

LAURUS LABS LTD share price has surged by 9% and its current market price is Rs 345. The BSE HEALTHCARE is up by 0.2%. The top gainers in the BSE HEALTHCARE Index are LAURUS LABS LTD (up 9.3%) and ASTRAZENECA PHARMA (up 6.0%). The top losers are ABBOTT INDIA (down 0.2%) and GLENMARK PHARMA (down 0.2%).

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Oct 23, 2019 10:55 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS